69 Dividend Champions Ranked By Quality Scores (November 2026)

The analysis ranks 69 Dividend Champions with Dividend Safety scores of at least 8 using its 9F Quality Scores system; 49 scored 7.0 or higher. It finds 22 undervalued and 21 overvalued, and names BRO and BMI as growth candidates; BRO, BMI, and RGLD (below $262) for total return; CTBI for income; and CAT for past performance.

Analysis

The signal here is a screening framework, not a fresh catalyst: the safety and quality scores are unverified inputs, and a dividend record does not neutralize valuation or sector risk. Treat the names as a research funnel rather than a basket recommendation.

BRO and BMI may offer different exposures—insurance distribution and water-metering demand, respectively—but both could be vulnerable if investors have already capitalized durable growth into elevated multiples. Verify valuation, organic growth and cash conversion before treating the rankings as upside. For BMI, municipal spending and replacement cycles are key checks; for BRO, organic growth and acquisition economics matter more than the dividend label.

CTBI’s income appeal is conditional on credit quality, deposit costs and net interest income; falling rates are not automatically positive if asset yields reprice faster than funding costs. RGLD offers gold-linked exposure, but real yields and gold prices—not a dividend-safety score—are likely to dominate near-term direction. CAT’s past performance is a weak forward signal: orders, end-market demand and dealer inventories matter more over the next cycle.

Near term, expect limited price impact absent adoption by investors or corroborating earnings revisions. Over 1–3 months, results and guidance can validate or undermine the screen. Over 6–18 months, valuation discipline and sector cycles should dominate. The contrarian risk is score/label anchoring: a “safe” dividend can still accompany a poor entry price or deteriorating fundamentals.

Key Decisions for Investors

• Do not buy the five-name list as a single dividend-quality trade. First verify the scoring methodology, valuation inputs, dividend coverage and the latest company guidance; those data are missing.
• Put BRO and BMI on a valuation-and-growth watchlist, not an automatic long. Consider entry only after confirming organic growth and cash conversion; reassess if growth or guidance weakens while valuation remains demanding.
• For CTBI, monitor credit trends, deposit costs and net interest income together. A deterioration in asset quality or funding costs would falsify the income case; do not infer rate upside from the dividend screen alone.
• Treat RGLD’s cited $262 level as the article author’s condition, not an independently supported target. Track gold and real yields before adding exposure; CAT likewise requires confirmation from orders and end-market indicators rather than backward-looking performance.